Literature DB >> 21447009

Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study.

Hamid Amoozgar1, Nahal Farhani, Neda Khodadadi, Mehran Karimi, Sirous Cheriki.   

Abstract

OBJECTIVES: To compare myocardial systolic and diastolic functions and pulmonary circulation by two-dimensional, M-mode, Doppler, and pulsed tissue Doppler imaging in patients with β-thalassemia intermedia who received hydroxyurea at least for 1 yr, patients who did not receive hydroxyurea, and a healthy control group.
METHODS: We assigned 84 patients with thalassemia intermedia into two groups: one of two was treated with hydroxyurea for at least 1 yr and no hydroxyurea. M-mode echocardiographic, Doppler, and pulsed Doppler tissue images were compared in these two groups and in 20 control participants who did not have thalassemia. For the estimation of pulmonary hypertension, pulmonary acceleration time below 100 ms was considered as an index of pulmonary hypertension.
RESULTS: There were no significant differences in M-mode echocardiographic findings between three groups. Doppler echocardiography detected no significant differences between the treated and untreated groups. In treated hydroxyurea group, 11.7% patients had pulmonary acceleration time below 100 ms and in untreated group 21% (LR = 1.45, P = 0.22). Pulsed Doppler tissue imaging parameters did not differ significantly between treated and untreated patients (P > 0.05). Pulsed Doppler tissue images showed significant changes between patients and controls in peak systolic velocity of the septum, peak atrial velocity of the septum (Aas), the peak systolic velocity of the tricuspid valve (St), the peak early diastolic velocity of the tricuspid valve (Eat), and the peak late diastolic velocity of the tricuspid valve (Aat).
CONCLUSION: This study revealed that in spite of decrease in estimated pulmonary hypertension in treated group, HU has no statistically significant effect on pulmonary acceleration time and M-mode, Doppler, and tissue Doppler changes of patients with TI.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447009     DOI: 10.1111/j.1600-0609.2011.01620.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 2.  Management of non-transfusion-dependent thalassemia: a practical guide.

Authors:  Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

3.  Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.

Authors:  Orly Leiva; Siyang Ren; Donna Neuberg; Ankeet Bhatt; Andrew Jenkins; Rachel Rosovsky; Rebecca Karp Leaf; Katayoon Goodarzi; Gabriela Hobbs
Journal:  Int J Hematol       Date:  2022-10-02       Impact factor: 2.319

Review 4.  Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

Authors:  Wai Cheng Foong; Jacqueline J Ho; C Khai Loh; Vip Viprakasit
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

Review 5.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

6.  Secondary haemochromatosis in a patient with thalassemia intermedia.

Authors:  Ionela Rotaru; Amelia Gaman; G Gaman
Journal:  Curr Health Sci J       Date:  2013-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.